Michael J. Morris

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.694Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386

Top 29%

0.694DataRank

Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Papers

Driven by 67 papers — median percentile 0. Top paper: “177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial”.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2

N/A

4.3DataRank · unranked

287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0855

N/A

2.2DataRank · unranked

68 citations

Christopher A. Klebanoff, David Schaer, John Kauh, Susan F. Slovin, Matthew Adamow +25 more

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00249-3

N/A

1.4DataRank · unranked

50 citations

Mark Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G. Aly, Noura J. Choudhury +14 more

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Cell(2022)10.1016/j.cell.2022.01.003

N/A

0.973DataRank · unranked

654 citations

Christopher J. Fong, Anisha Luthra, Shaleigh Smith, Renzo G. DiNatale, Subhiksha Nandakumar +70 more

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386

Top 29%

0.694DataRank

Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

Nature Communications(2024)10.1038/s41467-024-54847-1

N/A

0.571DataRank · unranked

21 citations

Bin Luo, Anna Kobilka, J. Lyman, Siyuan Guo, Sarah A. Munro +11 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

UNC Libraries(2020)10.17615/41rk-2070

N/A

0DataRank · unranked

0 citations

Matthew D. Galsky, Iain J. Webb, Jesika Petruck, Michael J. Morris, Robert Dreicer +7 more

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4573

N/A

0DataRank · unranked

387 citations

Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson +14 more

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)

The Journal of Urology(2021)10.1097/ju.0000000000001698

N/A

0DataRank · unranked

381 citations

Michael A. Gorin, Steven P. Rowe, Peter R. Carroll, Frédéric Pouliot, Stephan Probst +12 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.11.007

N/A

0DataRank · unranked

9 citations

Chong Hyun Suh, Andreas G. Wibmer, Anton S. Becker, Min Yuen Teo, Mithat Gönen +5 more

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2020.12.002

N/A

0DataRank · unranked

2 citations

Darren R. Feldman, Michael J. Morris, Robert J. Motzer, Dana E. Rathkopf, Ashley Marie Regazzi +5 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.11.01.466599

N/A

0DataRank · unranked

7 citations

Jimmy L. Zhao, Joseph M. Chan, Martine P. Roudier, Kristine M. Wadosky, Anuradha Gopalan +25 more

Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5022

N/A

0DataRank · unranked

1 citations

Kelsey Breen, Yelena Kemel, Andrew T. Lenis, Peter A. Reisz, Nicole Benfante +15 more

Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3

Journal of Nuclear Medicine(2022)10.2967/jnumed.121.263221

N/A

0DataRank · unranked

41 citations

Teja M. Kalidindi, Samantha Khitrov, Zachary V. Samuels, Goutam Chakraborty, Julia A. Gutierrez +7 more

From Concept to Regulatory Drug Approval: Lessons for Theranostics

Journal of Nuclear Medicine(2022)10.2967/jnumed.121.263301

N/A

0DataRank · unranked

24 citations

Michael J. Morris, Marlon Perera

Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases(2022)10.1038/s41391-022-00573-y

N/A

0DataRank · unranked

13 citations

Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz‐Snyderman, Azeez Farooki, Michael J. Morris +1 more

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

JNCI Cancer Spectrum(2022)10.1093/jncics/pkac035

N/A

0DataRank · unranked

11 citations

Vaibhav G. Patel, Xiaobo Zhong, Luis A. Pina, Jessica E. Hawley, Emily Lin +17 more

Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.02.002

N/A

0DataRank · unranked

7 citations

Glenn Heller, Joseph Fox, Daniel C. Danila, Anders Bjartell, Lars Edenbrandt +4 more

Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men’s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance])

European Urology Focus(2022)10.1016/j.euf.2022.03.007

N/A

0DataRank · unranked

3 citations

David Zahrieh, Devin Patel, James L. Mohler, Ronald C. Chen, Electra D. Paskett +12 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4607

N/A

0DataRank · unranked

12 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Ronald C. Chen, Timothy A. Chan +9 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194

N/A

0DataRank · unranked

5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107

N/A

0DataRank · unranked

4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

Use of bone modifying agents for metastatic castrate-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.055

N/A

0DataRank · unranked

0 citations

Akriti Mishra Meza, Azeez Farooki, Katherine S. Panageas, Peter B. Bach, Allison Lipitz‐Snyderman +2 more

Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.064

Top 100%

0DataRank

Top 100%0 citations

Samantha E. Vasselman, Ethan Barnett, Barbara Nweji, Emily Carbone, Alexander Blum +10 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661

N/A

0DataRank · unranked

29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT

Journal of Neuro-Oncology(2023)10.1007/s11060-023-04355-x

N/A

0DataRank · unranked

22 citations

Onur Yıldırım, Marc K. Rosenblum, Brandon S. Imber, J. Haseltine, Michael J. Zeléfsky +6 more

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad184

N/A

0DataRank · unranked

9 citations

Xiaofei Wang, Evan W. Warner, Andrea Sboner, Matti Annala, Michael Sigouros +13 more

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-23-9

N/A

0DataRank · unranked

5 citations

Justine Anderson, Daniel C. Danila, Michael J. Morris, Susan F. Slovin, Wassim Abida +5 more

Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer

The Prostate(2023)10.1002/pros.24636

N/A

0DataRank · unranked

2 citations

Sonia Persaud, Paul Palyca, Andrew Salner, Azeez Farooki, Jamie S. Ostroff +3 more

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5070

N/A

0DataRank · unranked

8 citations

Akash Roy, Siyuan S Guo, Larysa Rydzewska, Peter J. Godolphin, Maha Hussain +15 more

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps589

N/A

0DataRank · unranked

1 citations

Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy M. Faltas, Arshin Sheybani +11 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4609

N/A

0DataRank · unranked

1 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Srikala S. Sridhar, Ronald C. Chen +7 more

Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.12

N/A

0DataRank · unranked

1 citations

Nirjhar Chakraborty, David Nemirovsky, Akriti Mishra Meza, Sonia Persaud, Azeez Farooki +2 more

Barriers to guideline-concordant use of bone modifying agents for prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.68

N/A

0DataRank · unranked

0 citations

Sonia Persaud, Susan Chimonas, Andrew Salner, Paul Palyca, Azeez Farooki +3 more

Data from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

(2023)10.1158/1078-0432.c.6530694

N/A

0DataRank · unranked

0 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354.v1

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Data from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

(2023)10.1158/1078-0432.c.6530694.v1

N/A

0DataRank · unranked

0 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

Planning an enhanced telemedicine program for prostate cancer care: A qualitative assessment of patients,’ clinicians’, and other key stakeholders' interest and needs.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.454

N/A

0DataRank · unranked

0 citations

Kristina Stevanović, Allison Lipitz‐Snyderman, Michael J. Morris, Gilad J. Kuperman, Fernanda Polubriaginof +5 more

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3403

N/A

0DataRank · unranked

54 citations

Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong +25 more

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01535

N/A

0DataRank · unranked

29 citations

Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter J. Godolphin, Maha Hussain +15 more

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2061

N/A

0DataRank · unranked

27 citations

Michael J. Morris, Chien‐Kuang Cornelia Ding, Erolcan Sayar, Rohit Mehra, Brian D. Robinson +10 more

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0803

N/A

0DataRank · unranked

10 citations

Olivia Bobek, Irenaeus C.C. Chan, Brian C. Miller, David W. Hillman, Glenn Heller +8 more

Telemedicine and Cancer Care

The Cancer Journal(2024)10.1097/ppo.0000000000000691

N/A

0DataRank · unranked

25 citations

Erin M. Bange, Bobby Daly, Gilad J. Kuperman, Katherine S. Panageas, Michael J. Morris +1 more

A Framework for Integrating Telehealth Equitably across the cancer care continuum

JNCI Monographs(2024)10.1093/jncimonographs/lgae021

N/A

0DataRank · unranked

16 citations

Andy S.L. Tan, Bonnie Spring, Erin M. Bange, Allison Lipitz‐Snyderman, Michael J. Morris +13 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0DataRank · unranked

7 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer

European Urology Oncology(2024)10.1016/j.euo.2024.07.007

N/A

0DataRank · unranked

5 citations

Hebert Alberto Vargas, Daniel J. Holzwanger, Heiko Schöder, Emily Waters, Elena N. Petre +13 more

Transforming patient-centered cancer care using telehealth: the MATCHES Center

JNCI Monographs(2024)10.1093/jncimonographs/lgae004

N/A

0DataRank · unranked

5 citations

Robert Michael Daly, Allison Lipitz‐Snyderman, Gilad J. Kuperman, Fernanda Polubriaginof, Chris Liebertz +12 more

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00794-3

N/A

0DataRank · unranked

3 citations

Yingmiao Liu, Qian Yang, Bin Luo, Mark D. Starr, John C. Brady +7 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

First-in-human imaging with [ 89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate

medRxiv(2024)10.1101/2024.01.10.24301109

N/A

0DataRank · unranked

4 citations

Mark Dunphy, Matthew Agee, Joseph A. O’Donoghue, Rania G. Aly, Noura J. Choudhury +14 more

Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions

Current Oncology Reports(2025)10.1007/s11912-025-01686-y

N/A

0DataRank · unranked

8 citations

Michael J. Morris, Eric H. Bent

Symptomatic Prostate-Specific Membrane Antigen PET–Positive Radionecrosis After Multimodality Brain Metastasis–Directed Treatment Including [177Lu]Lu-PSMA-617

Journal of Nuclear Medicine(2025)10.2967/jnumed.124.269175

N/A

0DataRank · unranked

1 citations

Kenny Yu, Wassim Abida, Luke Pike, Milan Grkovski, Thomas Kaley +10 more

Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.246

N/A

0DataRank · unranked

0 citations

Hyotae Kim, Michael J. Morris, Mohammad Alyamani, Roberto Diaz, Himisha Beltran +4 more

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.264

N/A

0DataRank · unranked

0 citations

Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson +7 more

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2483

N/A

0DataRank · unranked

21 citations

Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa +10 more

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Cancer(2020)10.1002/cncr.33169

N/A

0DataRank · unranked

15 citations

Toni K. Choueiri, Marion Feuilly, Jie Meng, J. Lister, Florence Marteau +5 more

A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2019.10.013

N/A

0DataRank · unranked

33 citations

Jay Chudow, Mia DeNunzio, Susan F. Slovin, Daniel C. Danila, Michael J. Morris +3 more

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

The Prostate(2020)10.1002/pros.24056

N/A

0DataRank · unranked

28 citations

Kenneth J. Pienta, John W. Babich, Neil H. Bander, Jérémie Calais, Peter L. Choyke +11 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol - A191402CD - A Cluster-Randomized Trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e24176

N/A

0DataRank · unranked

0 citations

Joel E. Pacyna, Daniel G. Petereit, Judith S. Kaur, Bruce D. Rapkin, Robert L. Grubb +15 more

Michael J. Morris

Indexed papers

Top data-sharing exemplar

Papers